Last reviewed · How we verify
Bimatoprost and Timolol
At a glance
| Generic name | Bimatoprost and Timolol |
|---|---|
| Also known as | Bimatoprost 0.03%/timolol 0.5% fixed combination |
| Sponsor | Afyon Kocatepe University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) (PHASE3)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) (PHASE3)
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (PHASE1, PHASE2)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost and Timolol CI brief — competitive landscape report
- Bimatoprost and Timolol updates RSS · CI watch RSS
- Afyon Kocatepe University Hospital portfolio CI